

Stephen L Hauser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4756862/publications.pdf>

Version: 2024-02-01

135
papers

18,199
citations

27035

58
h-index

15698

129
g-index

139
all docs

139
docs citations

139
times ranked

16656
citing authors

#	ARTICLE	IF	CITATIONS
1	Polygenic risk score association with multiple sclerosis susceptibility and phenotype in Europeans. <i>Brain</i> , 2023, 146, 645-656.	3.7	15
2	Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials. <i>European Journal of Neurology</i> , 2022, 29, 1238-1242.	1.7	9
3	A smartphone sensor-based digital outcome assessment of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 654-664.	1.4	51
4	Building a Precision Medicine Delivery Platform for Clinics: The University of California, San Francisco, BRIDGE Experience. <i>Journal of Medical Internet Research</i> , 2022, 24, e34560.	2.1	6
5	Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis. <i>Annals of Neurology</i> , 2022, 91, 268-281.	2.8	39
6	Simultaneous assessment of regional distributions of atrophy across the neuraxis in MS patients. <i>NeuroImage: Clinical</i> , 2022, 34, 102985.	1.4	5
7	Multiple sclerosis: two decades of progress. <i>Lancet Neurology</i> , The, 2022, 21, 211-214.	4.9	16
8	Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials. <i>Frontiers in Immunology</i> , 2022, 13, 852563.	2.2	18
9	Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1576-1590.	1.4	24
10	Reply to "Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS". <i>Annals of Neurology</i> , 2022, 91, 735-736.	2.8	0
11	KIR2DL1+ CD8+ T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19. <i>Science</i> , 2022, 376, eabi9591.	6.0	113
12	Efficacy and safety of ofatumumab in recently diagnosed, treatment-naïve patients with multiple sclerosis: Results from ASCLEPIOS I and II. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1562-1575.	1.4	25
13	Challenges to Longitudinal Characterization of Lower Urinary Tract Dysfunction in Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 62, 103793.	0.9	3
14	An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1432-1441.	1.4	9
15	Retinal INL Thickness in Multiple Sclerosis: A Mere Marker of Neurodegeneration?. <i>Annals of Neurology</i> , 2021, 89, 192-193.	2.8	14
16	Role of B Cells in Multiple Sclerosis and Related Disorders. <i>Annals of Neurology</i> , 2021, 89, 13-23.	2.8	123
17	Antigen Presentation by B Cells in Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2021, 384, 378-381.	13.9	18
18	High Resolution Haplotype Analyses of Classical HLA Genes in Families With Multiple Sclerosis Highlights the Role of HLA-DP Alleles in Disease Susceptibility. <i>Frontiers in Immunology</i> , 2021, 12, 644838.	2.2	5

#	ARTICLE	IF	CITATIONS
19	Curing Multiple Sclerosis: How to Know When We're There. <i>Annals of Neurology</i> , 2021, 90, 539-541.	2.8	5
20	Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e1546-e1559.	1.5	75
21	Cell type-specific transcriptomics identifies neddylation as a novel therapeutic target in multiple sclerosis. <i>Brain</i> , 2021, 144, 450-461.	3.7	16
22	Electronic Health Record Technology Designed for the Clinical Encounter: MS NeuroShare. <i>Neurology: Clinical Practice</i> , 2021, 11, 318-326.	0.8	2
23	Electronic Health Record Technology Designed for the Clinical Encounter. <i>Neurology: Clinical Practice</i> , 2021, 11, 318-326.	0.8	11
24	Specific hypomethylation programs underpin B cell activation in early multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	14
25	Intersubject Variability and Normalization Strategies for Spinal Cord Total Cross-sectional and Gray Matter Areas. <i>Journal of Neuroimaging</i> , 2020, 30, 110-118.	1.0	31
26	Five years of ocrelizumab in relapsing multiple sclerosis. <i>Neurology</i> , 2020, 95, e1854-e1867.	1.5	81
27	Treatment of Multiple Sclerosis: A Review. <i>American Journal of Medicine</i> , 2020, 133, 1380-1390.e2.	0.6	374
28	Gut microbiota-specific IgA ⁺ B cells traffic to the CNS in active multiple sclerosis. <i>Science Immunology</i> , 2020, 5, .	5.6	132
29	Imaging correlates of visual function in multiple sclerosis. <i>PLoS ONE</i> , 2020, 15, e0235615.	1.1	5
30	Ofatumumab versus Teriflunomide in Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2020, 383, 546-557.	13.9	358
31	Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , The, 2020, 19, 998-1009.	4.9	98
32	Ataxin-1 regulates B cell function and the severity of autoimmune experimental encephalomyelitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 23742-23750.	3.3	14
33	A pathogenic and clonally expanded B cell transcriptome in active multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 22932-22943.	3.3	119
34	Neurite Orientation Dispersion and Density Imaging for Assessing Acute Inflammation and Lesion Evolution in MS. <i>American Journal of Neuroradiology</i> , 2020, 41, 2219-2226.	1.2	14
35	Progress in Multiple Sclerosis Research. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 841.	3.8	9
36	Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. <i>JAMA Neurology</i> , 2020, 77, 1132.	4.5	245

#	ARTICLE	IF	CITATIONS
37	Serum antibodies to phosphatidylcholine in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e765.	3.1	10
38	Brain MRI Predicts Worsening Multiple Sclerosis Disability over 5 Years in the SUMMIT Study. <i>Journal of Neuroimaging</i> , 2020, 30, 212-218.	1.0	11
39	A Precision Medicine Tool for Patients With Multiple Sclerosis (the Open MS BioScreen): Human-Centered Design and Development. <i>Journal of Medical Internet Research</i> , 2020, 22, e15605.	2.1	23
40	Imaging correlates of visual function in multiple sclerosis. , 2020, 15, e0235615.		0
41	Imaging correlates of visual function in multiple sclerosis. , 2020, 15, e0235615.		0
42	Imaging correlates of visual function in multiple sclerosis. , 2020, 15, e0235615.		0
43	Imaging correlates of visual function in multiple sclerosis. , 2020, 15, e0235615.		0
44	Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1526-1534.	1.4	49
45	Opposing T cell responses in experimental autoimmune encephalomyelitis. <i>Nature</i> , 2019, 572, 481-487.	13.7	141
46	Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years. <i>JAMA Neurology</i> , 2019, 76, 1359.	4.5	129
47	Reply to "Silent Progression or Bout Onset Progressive Multiple Sclerosis?" <i>Annals of Neurology</i> , 2019, 86, 472-473.	2.8	2
48	Telomere Length Is Associated with Disability Progression in Multiple Sclerosis. <i>Annals of Neurology</i> , 2019, 86, 671-682.	2.8	41
49	Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. <i>Neurology</i> , 2019, 93, e1778-e1786.	1.5	37
50	Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. <i>Science</i> , 2019, 365, .	6.0	710
51	pRNFL as a marker of disability worsening in the medium/long term in patients with MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e533.	3.1	18
52	Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 30, 236-243.	0.9	69
53	Nucleic Acid-Based Therapeutics Relevant to Neuroimmune Conditions. <i>Neurotherapeutics</i> , 2019, 16, 314-318.	2.1	2
54	Sex-specific Tau methylation patterns and synaptic transcriptional alterations are associated with neural vulnerability during chronic neuroinflammation. <i>Journal of Autoimmunity</i> , 2019, 101, 56-69.	3.0	11

#	ARTICLE	IF	CITATIONS
55	A specific amino acid motif of <i>HLA-DRB1</i> mediates risk and interacts with smoking history in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7419-7424.	3.3	58
56	Silent progression in disease activity-free relapsing multiple sclerosis. Annals of Neurology, 2019, 85, 653-666.	2.8	265
57	Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology, 2019, 266, 1182-1193.	1.8	61
58	Anti-CD20 therapy depletes activated myelin-specific CD8 ⁺ T cells in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 25800-25807.	3.3	71
59	Contribution of normal aging to brain atrophy in MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	3.1	57
60	Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions. Multiple Sclerosis Journal, 2019, 25, 1915-1925.	1.4	122
61	B-Cell Therapies in Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a032037.	2.9	60
62	Harnessing electronic medical records to advance research on multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 408-418.	1.4	21
63	Longitudinally persistent cerebrospinal fluid B-cells can resist treatment in multiple sclerosis. JCI Insight, 2019, 4, .	2.3	22
64	Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study. Journal of Medical Internet Research, 2019, 21, e14863.	2.1	90
65	Ovarian aging is associated with gray matter volume and disability in women with MS. Neurology, 2018, 90, e254-e260.	1.5	41
66	Diagnosing multiple sclerosis: art and science. Lancet Neurology, The, 2018, 17, 109-111.	4.9	9
67	Thalamic atrophy in multiple sclerosis: A magnetic resonance imaging marker of neurodegeneration throughout disease. Annals of Neurology, 2018, 83, 223-234.	2.8	169
68	Aberrant STAT phosphorylation signaling in peripheral blood mononuclear cells from multiple sclerosis patients. Journal of Neuroinflammation, 2018, 15, 72.	3.1	18
69	No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731876064.	0.5	32
70	Rituximab before and during pregnancy. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e453.	3.1	159
71	SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts. Multiple Sclerosis Journal, 2018, 24, 1485-1498.	1.4	19
72	B-cell Therapy for Multiple Sclerosis: Entering an era. Annals of Neurology, 2018, 83, 13-26.	2.8	179

#	ARTICLE	IF	CITATIONS
73	Body mass index, but not vitamin D status, is associated with brain volume change in MS. <i>Neurology</i> , 2018, 91, e2256-e2264.	1.5	65
74	Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. <i>Cell</i> , 2018, 175, 1679-1687.e7.	13.5	115
75	Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. <i>Annals of Neurology</i> , 2018, 84, 527-536.	2.8	42
76	Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017, 376, 1692-1694.	13.9	50
77	Onset of secondary progressive <sc>MS</sc> after long-term rituximab therapy – a case report. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 46-52.	1.7	22
78	Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017, 376, 221-234.	13.9	1,322
79	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017, 376, 209-220.	13.9	1,324
80	Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. <i>Lancet</i> , The, 2017, 390, 2481-2489.	6.3	377
81	Infliximab for the treatment of CNS sarcoidosis. <i>Neurology</i> , 2017, 89, 2092-2100.	1.5	151
82	Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10713-10718.	3.3	709
83	Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis. <i>Neurotherapeutics</i> , 2017, 14, 835-841.	2.1	141
84	Advances in Imaging Multiple Sclerosis. <i>Seminars in Neurology</i> , 2017, 37, 538-545.	0.5	6
85	Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients. <i>JCI Insight</i> , 2017, 2, .	2.3	84
86	Long-term evolution of multiple sclerosis disability in the treatment era. <i>Annals of Neurology</i> , 2016, 80, 499-510.	2.8	331
87	Association of HLA Genetic Risk Burden With Disease Phenotypes in Multiple Sclerosis. <i>JAMA Neurology</i> , 2016, 73, 795.	4.5	64
88	Power estimation for non-standardized multisite studies. <i>NeuroImage</i> , 2016, 134, 281-294.	2.1	36
89	Advancing ethical neuroscience. <i>Annals of Neurology</i> , 2015, 77, 735-737.	2.8	0
90	2D phase-sensitive inversion recovery imaging to measure in vivo spinal cord gray and white matter areas in clinically feasible acquisition times. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 42, 698-708.	1.9	29

#	ARTICLE	IF	CITATIONS
91	Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis. JAMA Neurology, 2015, 72, 897.	4.5	78
92	High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nature Genetics, 2015, 47, 172-179.	9.4	280
93	Mitochondrial DNA sequence variation in multiple sclerosis. Neurology, 2015, 85, 325-330.	1.5	60
94	An ImmunoChip study of multiple sclerosis risk in African Americans. Brain, 2015, 138, 1518-1530.	3.7	60
95	Hematopoietic Stem Cell Transplantation for MS. JAMA - Journal of the American Medical Association, 2015, 313, 251.	3.8	5
96	Genetic contribution to multiple sclerosis risk among Ashkenazi Jews. BMC Medical Genetics, 2015, 16, 55.	2.1	8
97	Class II HLA interactions modulate genetic risk for multiple sclerosis. Nature Genetics, 2015, 47, 1107-1113.	9.4	312
98	The Charcot Lecture Beating MS: A story of B cells, with twists and turns. Multiple Sclerosis Journal, 2015, 21, 8-21.	1.4	91
99	Age, Gender and Normalization Covariates for Spinal Cord Gray Matter and Total Cross-Sectional Areas at Cervical and Thoracic Levels: A 2D Phase Sensitive Inversion Recovery Imaging Study. PLoS ONE, 2015, 10, e0118576.	1.1	54
100	In multiple sclerosis, oligoclonal bands connect to peripheral B cell responses. Annals of Neurology, 2014, 75, 266-276.	2.8	73
101	Magnetic Resonance Spectroscopy Markers of Disease Progression in Multiple Sclerosis. JAMA Neurology, 2014, 71, 840.	4.5	57
102	Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis. Science Translational Medicine, 2014, 6, 248ra106.	5.8	194
103	Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Annals of Neurology, 2014, 76, 568-580.	2.8	158
104	Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients. Journal of Immunology, 2014, 193, 580-586.	0.4	223
105	Precision medicine in chronic disease management: The multiple sclerosis screen. Annals of Neurology, 2014, 76, 633-642.	2.8	53
106	Multiple sclerosis: Prospects and promise. Annals of Neurology, 2013, 74, 317-327.	2.8	165
107	Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls. Human Molecular Genetics, 2013, 22, 4194-4205.	1.4	81
108	Tob1 plays a critical role in the activation of encephalitogenic T cells in CNS autoimmunity. Journal of Experimental Medicine, 2013, 210, 1301-1309.	4.2	40

#	ARTICLE	IF	CITATIONS
109	B cell exchange across the blood-brain barrier in multiple sclerosis. <i>Journal of Clinical Investigation</i> , 2012, 122, 4533-4543.	3.9	211
110	Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. <i>Lancet, The</i> , 2011, 378, 1779-1787.	6.3	636
111	Abnormal B cell cytokine responses a trigger of T cell-mediated disease in MS?. <i>Annals of Neurology</i> , 2010, 67, 452-461.	2.8	428
112	B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2008, 358, 676-688.	13.9	2,107
113	Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 11839-11844.	3.3	105
114	The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration. <i>Neuron</i> , 2006, 52, 61-76.	3.8	666
115	An update on multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2005, 228, 193-194.	0.3	6
116	Linkage and association analysis of chromosome 19q13 in multiple sclerosis. <i>Neurogenetics</i> , 2001, 3, 195-201.	0.7	33
117	Experimental allergic encephalomyelitis in the New World monkey <i>Callithrix jacchus</i> . <i>Immunological Reviews</i> , 2001, 183, 159-172.	2.8	81
118	Frequency, heterogeneity and encephalitogenicity of T cells specific for myelin oligodendrocyte glycoprotein in naive outbred primates. <i>European Journal of Immunology</i> , 2001, 31, 2942-2950.	1.6	54
119	Characterization of the response to myelin basic protein in a non human primate model for multiple sclerosis. <i>European Journal of Immunology</i> , 2001, 31, 474-479.	1.6	9
120	Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination. <i>Journal of Clinical Immunology</i> , 2001, 21, 155-170.	2.0	99
121	PTPRC (CD45) is not associated with the development of multiple sclerosis in U.S. patients. <i>Nature Genetics</i> , 2001, 29, 23-24.	9.4	65
122	Identification of autoantibodies associated with myelin damage in multiple sclerosis. <i>Nature Medicine</i> , 1999, 5, 170-175.	15.2	826
123	Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: A case for antigen-specific antibody mediation. <i>Annals of Neurology</i> , 1999, 46, 144-160.	2.8	273
124	Multiple Sclerosis: Basic Immunology. <i>Journal of Spinal Cord Medicine</i> , 1998, 21, 106-108.	0.7	3
125	Creation of a model for multiple sclerosis in <i>Callithrix jacchus</i> marmosets. <i>Journal of Molecular Medicine</i> , 1997, 75, 187-197.	1.7	76
126	Genetics of Demyelinating Diseases. <i>Brain Pathology</i> , 1996, 6, 289-302.	2.1	50

#	ARTICLE	IF	CITATIONS
127	Active and passively induced experimental autoimmune encephalomyelitis in common marmosets: A new model for multiple sclerosis. <i>Annals of Neurology</i> , 1995, 37, 519-530.	2.8	132
128	Prevention strategies for multiple sclerosis. <i>Annals of Neurology</i> , 1994, 36, S157-S162.	2.8	2
129	The T-cell response to myelin basic protein in familial multiple sclerosis: Diversity of fine specificity, restricting elements, and T-cell receptor usage. <i>Annals of Neurology</i> , 1993, 34, 385-393.	2.8	59
130	Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's disease. <i>Annals of Neurology</i> , 1992, 32, 733-742.	2.8	52
131	Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. <i>Annals of Neurology</i> , 1986, 19, 578-587.	2.8	355
132	Autoimmunity following viral infection: demonstration of monoclonal antibodies against normal tissue following infection of mice with reovirus and demonstration of shared antigenicity between virus and lymphocytes. <i>European Journal of Immunology</i> , 1984, 14, 561-565.	1.6	43
133	Immunoregulatory T-cells and lymphocytotoxic antibodies in active multiple sclerosis: Weekly analysis over a six-month period. <i>Annals of Neurology</i> , 1983, 13, 418-425.	2.8	90
134	Clonally restricted B cells in peripheral blood of multiple sclerosis patients: Kappa/lambda staining patterns. <i>Annals of Neurology</i> , 1982, 11, 408-412.	2.8	11
135	Childhood multiple sclerosis: Clinical features and demonstration of changes in T cell subsets with disease activity. <i>Annals of Neurology</i> , 1982, 11, 463-468.	2.8	60